Protagonist Therapeutics, Inc.
PTGX
$44.27
-$1.00-2.21%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -34.02% | 624.06% | -- | -- | 36,565.08% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -34.02% | 624.06% | -- | -- | 36,565.08% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -34.02% | 624.06% | -- | -- | 36,565.08% |
| SG&A Expenses | 1.24% | 29.77% | 32.71% | 27.96% | 33.41% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.60% | 18.18% | 14.01% | 13.37% | 13.00% |
| Operating Income | -81.69% | 369.98% | 197.32% | 203.43% | 201.64% |
| Income Before Tax | -65.49% | 453.88% | 223.20% | 225.43% | 218.01% |
| Income Tax Expenses | -73.12% | -- | -- | -- | -- |
| Earnings from Continuing Operations | -65.34% | 448.54% | 221.61% | 223.50% | 215.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -65.34% | 448.54% | 221.61% | 223.50% | 215.64% |
| EBIT | -81.69% | 369.98% | 197.32% | 203.43% | 201.64% |
| EBITDA | -81.25% | 373.72% | 198.58% | 204.81% | 203.02% |
| EPS Basic | -65.83% | 405.40% | 207.96% | 204.11% | 191.97% |
| Normalized Basic EPS | -66.01% | 410.04% | 209.36% | 205.73% | 193.90% |
| EPS Diluted | -69.04% | 382.22% | 201.24% | 197.50% | 185.69% |
| Normalized Diluted EPS | -69.10% | 388.89% | 203.27% | 199.77% | 188.27% |
| Average Basic Shares Outstanding | 4.71% | 8.52% | 13.22% | 17.51% | 19.80% |
| Average Diluted Shares Outstanding | 4.60% | 10.84% | 15.14% | 19.52% | 21.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |